It is one of the most common therapeutics used in BC and appears to be one of the most important for patients with triple‐negative breast cancer (TNBC), characterized by the absence of estrogen, progesterone, and HER2/neu receptors, and thus unavailable for hormonal therapy (Minotti et al., 2004; Nicoletto & Ofner, 2022). Here, ERBB2 is linked to breast cancer.